ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0842 • ACR Convergence 2024

    The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)

    Reyhan Kose Cobanoglu1, Rohan Willis2, Diana Paredes-Ruiz3, Maria G Tektonidou4, Vittorio Pengo5, Savino Sciascia6, Cecilia Nalli7, Flavio Victor Signorelli8, Paul Fortin9, Maria Efthymiou10, H Michael Belmont11, Michelle Petri12, Ricard Cervera13, Megan Barber14, TATSUYA ATSUMI15, Chary Lopez-Pedrera16, Jason Knight17, David Branch18, Nina Kello19, Lanlan Ji20, Esther Rodriguez-Almaraz21, Bahar Artim Esen22, Jose Pardos Gea23, Rosana Quintana24, Giulia Pazzola25, Hui Shi26, Ali Duarte-Garcia27, Pierluigi Meroni28, Robert Roubey29, Maria Laura Bertolaccini30, Hannah Cohen31, Danieli Andrade32 and Doruk Erkan33, and on behalf of APS ACTION, 1Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 2University of Texas Medical Branch, Galveston, TX, 3Biocruces Bizkaia Health Research Institute, Bizkaia, Spain, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Torino, Turin, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 9Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 10University College London, London, United Kingdom, 11NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 15Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 16IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 17University of Michigan, Ann Arbor, MI, 18University of Utah and Intermountain Healthcare, Salt Lake City, UT, 19Northwell Health, Brooklyn, NY, 20Peking University First Hospital, Peking, China (People's Republic), 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 23Vall d'Hebron University Hospital, Barcelona, Spain, 24Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 25Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 26Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), 27Mayo Clinic, Rochester, MN, 28IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 29Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 30King's College London, London, United Kingdom, 31University College London Hospitals NHS Foundation Trust, London, United Kingdom, 32University of São Paulo, São Paulo, SP, Brazil, 33Hospital for Special Surgery, New York, NY

    Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases…
  • Abstract Number: 0106 • ACR Convergence 2024

    IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS

    Christina Donath1, Sara Kahlown1, Ryan Soares2, Kamal Gautam2, Mariam Saleh3, Banki Katalin4 and Andras Perl5, 1SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, 2SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, 3SUNY Upstate University Hospital, Syracuse, NY, 4SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, 5SUNY, Syracuse, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
  • Abstract Number: 0122 • ACR Convergence 2024

    Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome

    Evelyn Aranda Cano1, Jessica Roldan Ortega2, Yaneli Juárez-Vicuña3, Fausto Sánchez Muñoz4, Itzel Palafox Sosa5, Luz Angelica Viruel-Mejia6, David Vera Bustamante7, Luis H. Silveira Torre8, Angélica Vargas Guerrero9, Mayra Nadia Quintanar-Cuevas10, Erick Giovanny Bautista Jímenez11 and Laura Aline Martinez-Martinez12, 1Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, 2Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 3Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, 4Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 5Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, 6Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, 7Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, 8Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 9Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 10Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, 11Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, 12Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
  • Abstract Number: 0915 • ACR Convergence 2024

    APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism

    Yiming Luo, Lili Liu, Atlas Khan, R. Graham Barr, Elana Bernstein and Krzysztof Kiryluk, Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Anti-Beta-2-glycoprotein 1 antibody (anti-B2GP1) is associated with antiphospholipid syndrome (APS), a rare autoimmune disease that causes venous thromboembolism (VTE). APOH, which expresses the B2GP1…
  • Abstract Number: 0107 • ACR Convergence 2024

    Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study

    Yachar DAWUDI1, Charlotte Gourmelon2, Arthur Mageau3, Bénédicte DUMONT4, Hélène HELFER4, Diane ROUZAUD1, Thomas Papo3, Isabelle MAHE5, Pascale Roland-Nicaise6 and Karim Sacré3, 1Assistance Publique Hôpitaux de Paris, Paris, France, 2Université Paris Saclay, Paris, France, 3Université Paris Cité, Paris, France, 4Assistance Publique Hôpitaux de Paris, Colombes, France, 5Université Paris Cité, Colombes, France, 6Laboratoire d'immunologie, Hôpital Bichat, AP-HP, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thromboses and/or pregnancy morbidity in the presence of persistent antiphospholipid autoantibodies (aPL)…
  • Abstract Number: 0123 • ACR Convergence 2024

    The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)

    Carla Silva1 and Danieli Andrade2, 1University of Sao Paulo, Salvador, Bahia, Brazil, 2University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality,…
  • Abstract Number: 1111 • ACR Convergence 2024

    Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism

    Kessiena Aomreore, Lincoln Medical Center, New york, NY

    Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
  • Abstract Number: 0108 • ACR Convergence 2024

    Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)

    Fernanda Oliveira de Andrade Lopes1, Andreia Coimbra Sousa2, Massimo Radin3, Gustavo Balbi4, Irene Cecchi3, Savino Sciascia5, Flavio Victor Signorelli6 and Danieli Andrade2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2University of São Paulo, São Paulo, SP, Brazil, 3University of Turin, Turin, Italy, 4Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, 5University of Turin, Torino, Turin, Italy, 6Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
  • Abstract Number: 0124 • ACR Convergence 2024

    Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates

    Jonathan Campos-Guzmán1, María Espinosa-León2, Iris Paola García Herrera1, Iris Jazmín Colunga Pedraza3, Mariel Martínez-Ruiz1, Ana Barrera-Vargas4, Guillermo Guaracha Basañez5 and javier Merayo Chalico6, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, 5Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, 6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic thromboinflammatory disease with various forms of presentation. There is limited information on sexual function in patients with APS,…
  • Abstract Number: 1240 • ACR Convergence 2024

    Living with Antiphospholipid Antibodies: A Photovoice Exploration

    Francesca Cardwell1, Susan J. Elliott2, Paul S. Gibson3, Nancy Soliman4, Leslie Skeith4, Ann E. Clarke5 and Megan Barber5, 1University of Waterloo, Burlington, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4University of Calgary, Calgary, ON, Canada, 5Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…
  • Abstract Number: 0109 • ACR Convergence 2024

    Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Rohan Willis1, Anne Tebo2, Leslie Skeith3, Nina Kello4, H Michael Belmont5, Paul Fortin6, Guilherme Ramires de Jesús7, David Branch8, Michelle Petri9, Jason Knight10, Reyhan Kose Cobanoglu11, Maria Laura Bertolaccini12, Hannah Cohen13, Robert Roubey14, Doruk Erkan15 and Danieli Andrade16, and on behalf of APS ACTION, 1University of Texas Medical Branch, Galveston, TX, 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3University of Calgary, Calgary, ON, Canada, 4Northwell Health, Brooklyn, NY, 5NYU School of Medicine, New York, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 8University of Utah and Intermountain Healthcare, Salt Lake City, UT, 9Johns Hopkins University School of Medicine, Timonium, MD, 10University of Michigan, Ann Arbor, MI, 11Aydin Adnan Menderes University School of Medicine, Hospital for Special Surgery, NY, USA, Aydin, Turkey, 12King's College London, London, United Kingdom, 13University College London Hospitals NHS Foundation Trust, London, United Kingdom, 14Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 15Hospital for Special Surgery, New York, NY, 16University of São Paulo, São Paulo, SP, Brazil

    Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…
  • Abstract Number: 0125 • ACR Convergence 2024

    Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome

    Emily Balczewski1, Amala Ambati2, Wenying Liang1, Jacqueline Madison1, Yu Zuo1, Karandeep Singh3 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Toledo, OH, 3University of California -- San Diego, San Diego, CA

    Background/Purpose: Electronic health record (EHR) data provide a widely available, inexpensive, and information-rich tool that is underutilized in the research of rare diseases like antiphospholipid…
  • Abstract Number: 1267 • ACR Convergence 2024

    Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Jheel Pandya1, Danieli Andrade2, Ann E. Clarke3, Maria Tektonidou4, Vittorio Pengo5, Massimo Radin6, Jose Pardos-Gea7, Nina Kello8, Diana Paredes-Ruiz9, Mª Angeles Aguirre-Zamorano10, H Michael Belmont11, Paul Fortin12, Flavio Victor Signorelli13, TATSUYA ATSUMI14, Zhuoli Zhang15, Maria Efthymiou16, David Branch17, Giulia Pazzola18, Angela Tincani19, Ali Duarte-Garcia20, Esther Rodriguez-Almaraz21, Michelle Petri22, Ricard Cervera23, Bahar Artim Esen24, Guillermo Pons-Estel25, Hui Shi26, Yu Zuo27, Rohan Willis28, Pierluigi Meroni29, Robert Roubey30, Maria Laura Bertolaccini31, Hannah Cohen32 and Doruk Erkan1, and on behalf of APS ACTION, 1Hospital for Special Surgery, New York, NY, 2University of São Paulo, São Paulo, SP, Brazil, 3Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4National and Kapodistrian University of Athens, Athens, Greece, 5Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 6University of Turin, Turin, Italy, 7Vall d'Hebron University Hospital, Barcelona, Spain, 8Northwell Health, Brooklyn, NY, 9Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 10IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 11NYU School of Medicine, New York, NY, 12Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 13Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 14Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 15Peking University First Hospital, Beijing, China, 16University College London, London, United Kingdom, 17University of Utah and Intermountain Healthcare, Salt Lake City, UT, 18Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 19ASST Spedali Civili-University of Brescia, Brescia, Italy, 20Mayo Clinic, Rochester, MN, 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Johns Hopkins University School of Medicine, Timonium, MD, 23Hospital Clinic de Barcelona, Barcelona, Spain, 24Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 25CREAR, Rosario, Argentina, 26Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), 27University of Michigan, Ann Arbor, MI, 28University of Texas Medical Branch, Galveston, TX, 29IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 30Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom

    Background/Purpose: APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases. Given autoimmune diseases present differently in…
  • Abstract Number: 0110 • ACR Convergence 2024

    Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists

    Rohan Willis1, Vijaya Murthy2, Karen Roye-Green3, Amy Thees4, May Choi5, Ken Dier6, Marvin Fritzler7, Susan Fink8, Vijayalakshmi Nandakumar9, Melissa Snyder10 and Anne Tebo11, and the Association of Medical Laboratory Immunologists, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch (UTMB), League City, TX, 3University of the West Indies, Kingston, Jamaica, 4Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, 5University of Calgary, Calgary, AB, Canada, 6Corgenix, Broomfield, CO, 7Mitogen Diagnostics Corp, Calgary, AB, Canada, 8Clinical Immunology Laboratory, University of Washington Medical Center, Seattle, WA, 9ARUP/University of Utah, Salt Lake City, UT, 10Clinical Biochemistry and Immunology, Antibody Immunology Laboratory, Mayo Clinic, Rochester, MN, 11Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

    Background/Purpose: We have recently shown that anti-phospholipid (APL) assays of varying methodology demonstrate comparable analytical performance despite variable levels of agreement among individual analytes, identifying binding…
  • Abstract Number: 0126 • ACR Convergence 2024

    Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data

    Emily Balczewski1, Amala Ambati2, Wenying Liang1, Jacqueline Madison1, Yu Zuo1, Karandeep Singh3 and Jason Knight1, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Toledo, OH, 3University of California -- San Diego, San Diego, CA

    Background/Purpose: Antiphospholipid syndrome (APS) is a rare autoimmune disease that is likely to demonstrate improved outcomes with earlier diagnosis and treatment. However, given APS’s complex,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology